Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2051757 | 0.99 | HTT (0.43) | HTTMEN1KMT2APPARGHDAC6 | |
| SCHEMBL2052795 | 0.92 | HTT (0.44) | HTTMEN1KMT2APPARGHDAC6 | |
| SCHEMBL2016153 | 0.88 | HTT (0.44) | HTTMEN1KMT2APPARGHDAC6 | |
| Iodide SCHEMBL2019625 | 0.87 | HTT (0.43) | HTTMEN1KMT2APPARGHDAC6 | |
| SCHEMBL2019895 | 0.80 | HTT (0.44) | HTTMEN1KMT2APPARGHDAC6 | |
| Iodide SCHEMBL2019374 | 0.80 | HTT (0.43) | HTTMEN1KMT2APPARGHDAC6 | |
| SCHEMBL2051754 | 0.79 | MEN1 (0.64) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL2040435 | 0.78 | HTT (0.45) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL2016331 | 0.77 | HTT (0.52) | HTTMEN1KMT2ATP53LMNA | |
| SCHEMBL2053732 | 0.77 | LMNA (0.64) | HTTMEN1KMT2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |